经审慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将 从整体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问 题的解决时限、基本路径等做出进一步承诺，公司将在收到相关承诺文件后及时履行信息披露义务。中 国生物已根据前次避免同业竞争承诺函，及时向公司书面告知商业机会，已履行承诺函中的义务，不存 在违反承诺的情形。 智通财经APP讯，天坛生物(600161.SH)发布公告，近期，公司收到控股股东中国生物《关于投资商业 机会的通知函》，本次交易标的为派林生物控股股东胜帮英豪持有的其全部21.03%股份(简称"商业机 会")。由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业务构成同业竞争， 中国生物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同业竞争的承诺函》 (简称"前次避免同业竞争承诺函")，将其获得的与公司主营业务构成实质性同业竞争的新业务机会书面 通知公司。 ...

天坛生物（600161）(600161.SH)发布公告，近期，公司收到控股股东中国生物《关于投资商业机会的 通知函》，本次交易标的为派林生物（000403）控股股东胜帮英豪持有的其全部21.03%股份(简称"商业 机会")。由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业务构成同业竞 争，中国生物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同业竞争的承诺 函》(简称"前次避免同业竞争承诺函")，将其获得的与公司主营业务构成实质性同业竞争的新业务机会 书面通知公司。 经审慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将 从整体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问 题的解决时限、基本路径等做出进一步承诺，公司将在收到相关承诺文件后及时履行信息披露义务。中 国生物已根据前次避免同业竞争承诺函，及时向公司书面告知商业机会，已履行承诺函中的义务，不存 在违反承诺的情形。 ...

人民财讯8月4日电，天坛生物（600161）8月4日晚间公告，近期，公司收到控股股东中国生物《关于投 资商业机会的通知函》，本次交易标的为派林生物（000403）控股股东胜帮英豪持有的其全部21.03% 股份(简称"商业机会")。由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业 务构成同业竞争，中国生物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同 业竞争的承诺函》，将其获得的与公司主营业务构成实质性同业竞争的新业务机会书面通知公司。经审 慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将从整 体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问题的 解决时限、基本路径等做出进一步承诺。 ...

经审慎分析研判，公司拟放弃收购派林生物商业机会。公司放弃收购派林生物商业机会后，中国生物将 从整体发展战略出发，实施派林生物商业机会的收购，中国生物完成本次收购后，将就新增同业竞争问 题的解决时限、基本路径等做出进一步承诺，公司将在收到相关承诺文件后及时履行信息披露义务。中 国生物已根据前次避免同业竞争承诺函，及时向公司书面告知商业机会，已履行承诺函中的义务，不存 在违反承诺的情形。 登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇8月4日丨天坛生物(600161.SH)公布，近期，公司收到控股股东中国生物《关于投资商业机会的 通知函》，本次交易标的为派林生物控股股东胜帮英豪持有的其全部21.03%股份（简称"商业机会"）。 由于派林生物主营业务为血液制品的研究、开发、生产和销售，与公司主营业务构成同业竞争，中国生 物根据2017年12月1日出具的《关于避免与北京天坛生物制品股份有限公司同业竞争的承诺函》，将其 获得的与公司主营业务构成实质性同业竞争的新业务机会书面通知公司。 ...

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]

Core Viewpoint - TianTan Biological experienced a sharp increase in stock price, reaching the daily limit, while other companies in the sector such as Keta Bio, Nanmo Bio, and Sairun Bio saw their stock prices rise by over 10% [1] Company Performance - TianTan Biological's stock price hit the daily limit, indicating strong market interest and confidence in the company [1] - Keta Bio, Nanmo Bio, and Sairun Bio also showed significant gains, with stock prices increasing by more than 10%, reflecting positive sentiment in the biotechnology sector [1] - Watson Bio and Anxu Bio, among others, followed suit with notable increases in their stock prices, suggesting a broader rally in the biotechnology industry [1]

8月4日突破年线个股乖离率排名 证券时报·数据宝统计，截至今日下午13:59，上证综指3568.96点，收于年线之上，涨跌幅为0.25%，A 股总成交额为11803.88亿元。到目前为止，今日有28只A股价格突破了年线，其中乖离率较大的个股有 天坛生物、光弘科技、中信海直等，乖离率分别为5.23%、4.69%、4.50%；桂冠电力、艾布鲁、蓝箭电 子等个股乖离率较小，刚刚站上年线。 （文章来源：证券时报网） | | 能 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 301587 | 中瑞股 | 1.04 | 1.39 | 23.33 | 23.38 | 0.22 | | | 份 | | | | | | | 300699 | 光威复 | 1.74 | 1.42 | 30.89 | 30.95 | 0.19 | | | 材 | | | | | | | 688337 | 普源精 | 2.21 | 3.39 | 35.10 | 35.16 | 0.16 | | | 电 | | | | | | | 300956 | 英力股 | 1.1 1 | 1.5 ...

Core Viewpoint - The A-share market saw a significant rise in biopharmaceutical stocks, particularly with notable gains from companies such as Nanmo Bio and Sairun Bio, following the completion of China's first Phase I clinical trial for an HIV vaccine using a modified smallpox virus as a carrier [1] Group 1: Market Performance - Biopharmaceutical stocks in the A-share market experienced a surge, with Nanmo Bio and Sairun Bio rising over 14% [1] - Tiantan Biological (600161) hit the daily limit with a 10% increase [1] - Other companies such as Zhijiang Bio, Watson Bio (300142), Rendu Bio, and Anxu Bio also saw gains [1] Group 2: Research and Development - The Chinese Center for Disease Control and Prevention's AIDS Prevention Center completed the first Phase I clinical trial for a replicative Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative research utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a carrier [1] - The trial confirmed the safety of the vaccine and its ability to elicit an effective immune response, marking a significant advancement in HIV vaccine development in China [1]

Group 1 - The core viewpoint of the article highlights the significant progress made in HIV vaccine research in China, with the completion of the first Phase I clinical trial of a recombinant Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector for the vaccine, demonstrating safety and the ability to elicit an effective immune response [1] - Following this announcement, the A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting the daily limit of 10% [1]

（文章来源：每日经济新闻） 每经AI快讯，8月4日，天坛生物直线拉升涨停，科拓生物、南模生物、赛伦生物涨超10%，沃森生物、 安旭生物等跟涨。 ...